CIPLA.NS Stock Analysis
CI
Neutral
Based on Eyestock quantitative analysis, CIPLA.NS`s fundamental data and valuation indicate an investment grade of Neutral at the current time.
Rating
To assess the quality of a company's business, we have collected all financial data from the statements and presented them in the form of a single number - the company's rating. Rating value of 100 is the threshold for determining a viable investment.
High score
Upside
To determine whether the current price is a reasonable to buy a stock, we compare it to our estimate of fair value. The more undervalued a stock is, the higher the upside.
Overvalued
Cipla Ltd. engages in the manufacture and distribution of healthcare products and bulk drugs. The company is headquartered in Mumbai, Maharashtra and currently employs 26,615 full-time employees. The firm operates through two segments: Pharmaceuticals and New ventures. The Pharmaceuticals segment is engaged in developing, manufacturing, selling, and distributing generic or branded generic medicines, as well as Active Pharmaceutical Ingredients (API). The New ventures segment includes the operations of the Company, a consumer healthcare, Biosimilars and specialty business. The firm's product portfolio spans complex generics, as well as drugs in the respiratory, anti-retroviral, urology, cardiology, anti-infective and central nervous system (CNS). The firm's geographical segments include India, the United States, South Africa, and Rest of the World. The firm has its network of manufacturing, trading and other incidental operations in India and International markets. The firm has approximately 47 manufacturing sites.